


The Growing Community of HL7

**Wes Rishel, Chair
HL7 Plenary Meeting
8 September 2003**

www.HL7.org



HL7 a “National” Asset



- Version 2
- Version 3
- CDA
- EHR
- CCOW
- FDA/CDISC
- NCVHS/CHI
- Vocabulary
- Educational Summits



V2: the Tool to Tap Existing Information Flows

- Widely implemented, not going away
- Challenge: uniform implementation
- Regional production use growing
- Demonstrated Use in US:
 - Winter Olympics BT
 - Healthcare Collaborative Network
 - CDC/NEDSS Lab Reporting
 - Empire BCBS and Labs



V3: the Tool for New Challenges

- NHS and GP2GP in England
- CDC/NEDSS Event Notification
- International Claims and other Admin transactions
- Canadian Provider and Patient Registries
- FDA/RCRIM Ballot Package for Clinical Trials

- A mark of progress:
 - Last year: use V3 tools to create “V3-like messages”
 - Now: submit those messages to ballot



Clinical Document Architecture

- Mayo Notes System
- CDISC/RCRIM/FDA Product Labeling
- CDISC Clinical Trials Operational Data Model
- Tumor reporting/CAP
- State confidential morbidity record
- HIPAA Claims Attachments
- Finland, Germany, UK, Ireland, Greece, Denmark, Japan
- Release 2.0 combined natural-language and V3 structured data

1. A basis for “computer assisted natural-language clinical documents”
2. A platform for more specific standards
3. Release 2: combined natural-language and structured data



Vocabulary

- The main challenge for increased interoperability
- Definition of “clinical drug” for RxNorm
- A system of domains and realms for coordinating vocabulary standards with messaging standards and supporting tooling
- Policy to make HL7’s tables freely available
- Direct collaboration with CHI on terminology
- Notable industry progress:
 - SNOMED contract with US Government
 - Adoption of Lab LOINC by HHS, VA, and DoD



EHR Functional Model

- Potential basis for funding of US EHR users
- A genuine “whirlwind” of activity
 - Since April two out of cycle meetings
 - IOM report received July 29th
 - EHR DSTU released August 5th
 - EHR Collaborative 6 city grass roots exposure weeks of August 11th & 18th. Almost 1000 participants.
 - EHR Ballot results. 247 total in ballot pool. 221 placed a vote.
- Why HL7? Process. If not HL7 who?
- Process challenges remain



V3 Ballot History - Overall

<i>Ballot cycle</i>	<i>8/2001</i>	<i>3/2002</i>	<i>8/2002</i>	<i>3/2003</i>	<i>8/2003</i>
Data Types Abstract	CCCCC	CCCCC	CCCCC	IIIIIII	MMMM
XML ITS Structures	CCCCC	CCCCC	CCCCC	CCCCC	CCCCC
Infrastructure Management	CCCCC	CCCCC	CCCCC	CCCCC	MMMM
CMETs	CCCCC	CCCCC	CCCCC	MMMM	MMMM
Accounting & Billing	CCCCC	CCCCC	CCCCC	CCCCC	CCCCC
Claims and Reimbursements	CCCCC	CCCCC	CCCCC	CCCCC	MMMM
Lab	CCCCC	CCCCC	CCCCC	CCCCC	FFFFFF
Medical Records	CCCCC	CCCCC	CCCCC	MMMM	MMMM
Patient Administration	CCCCC	CCCCC	CCCCC	CCCCC	CCCCC
Pharmacy	CCCCC	CCCCC	FFFFFF	CCCCC	FFFFFF
Scheduling	CCCCC	CCCCC	CCCCC	CCCCC	MMMM
XML ITS Data Types		CCCCC	CCCCC	CCCCC	CCCCC
Shared Messages		CCCCC	CCCCC	CCCCC	MMMM
RIM			CCCCC	MMMM	SSSSSS
Extensibility & Localization			CCCCC	MMMM	SSSSSS
Public Health Reporting				CCCCC	CCCCC
Regulated Studies				CCCCC	MMMM
Regulated Studies – ECG				IIIIIII	CCCCC
UML ITS – Data Types					CCCCC
Message Transport Spec					DDDDD
Patient Care					FFFFFF
Drug Product Labeling					CCCCC
CDA Level 2					CCCCC
Attachments					IIIIIII
EHR					IIIIIII



V3: Who is our customer? What is our competition?

- Customer
 - Governments?
 - Healthcare enterprises?
 - Vendors?
 - Programmers and analysts?
- Competition?
 - V2 -- “it’s a good thing”
 - Ad hoc, particular XML schemas



What Will Make V3 Succeed?

- Celebrate and listen to the early adopters
- Complexity: education or simplification? (Both)
- Push for clarity and usability, particularly for schemas
- Create a definition of what “done” means -- for our customers
 - What are the “done” deliverables for committees
- Revive the Implementation Committee, which was a keystone to the success of V2



HL7 Is, More Than Ever, a Community

- Related but diverse interests
- Cross-currents of collaboration
- Processes that work (but ever-evolving)
- and most important:
- Significant challenges

